Table 4.

Univariable and multivariable analyses of clinicopathologic parameters in association with overall survival (OS) in all patients

OS	Total n = 1178
Variable	Univariable Hazard ratio (95% CI)	P	Multivariable Hazard ratio (95% CI)	P
Age
≥ 65	1.18 (1.01, 1.37)	0.035	1.11 (0.73, 1.69)	0.795
ECOG-PS
≥ 2	1.09 (0.66, 1.79)	0.741
Historic subtype
SqCC	1.13 (0.96, 1.32)	0.150
Stage
IV	1.85 (1.25, 2.74)	0.002	1.23 (0.51, 3.82)	0.675
Smoking history
Yes	0.94 (0.79, 1.12)	0.487
PD-L1 TPS ≥ 50%
In both assays	0.69 (0.53, 0.89)	0.004	0.61 (0.40, 0.93)	0.022
In either assay	0.95 (0.80, 1.13)	0.573
EGFR
Positive	1.35 (1.07, 1.69)	0.011	1.89 (1.08, 3.31)	0.026
ALK
Positive	0.70 (0.43, 1.15)	0.160
Underlying autoimmune disease
Yes	1.19 (0.30, 4.79)	0.804
Co-malignancy
Yes	0.81 (0.58, 1.13)	0.214
irAE
Yes	0.55 (0.44, 0.68)	< .001	0.53 (0.33, 0.86)	0.001
Type of ICIs
Nivolumab	0.97 (0.83, 1.13)	0.690
Prior radiotherapy
Yes	1.24 (1.06, 1.46)	0.008	1.41 (0.83, 2.39)	0.206
RTx site
Distant metastatic sites	1.37 (1.10, 1.71)	0.005	1.06 (0.62,1.83)	0.824
Metastatic sites
Liver	1.05 (0.90, 1.23)	0.536
Lung	1.09 (0.93, 1.27)	0.296
Pleura	1.13 (0.95, 1.35)	0.166
Lymph node	1.06 (0.91, 1.23)	0.488
Adrenal gland	1.11 (0.87, 1.42)	0.405
Bone	1.45 (1.23, 1.70)	< .001	1.22 (0.76, 1.93)	0.412
Brain or LMS	1.24 (1.04, 1.48)	0.018	0.61 (0.36, 1.04)	0.067
Previous line of chemotherapy
≥ 2	1.05 (0.88, 1.26)	0.598

PS performance status, TPS tumor proportion score, irAE immune-related adverse events, ICIs immune-checkpoint inhibitors, RTx radiotherapy, LMS leptomeningeal seeding